Zoetis, the manufacturer behind the vaccine, announced the conditional approval Friday, saying in a news release its scientists had begun updating its existing avian flu vaccine in 2022.

Animal-drug maker Zoetis is alerting dog owners and veterinarians to potential debilitating side effects from a new arthritis injection that have caused some dogs to be euthanized. The company ...

In this article, we are going to take a look at where Zoetis Inc. (NYSE:ZTS) stands against the other best pharma stocks to buy according to hedge funds. Why is China the Talk of the Town in the ...

Zoetis, a leading global animal health company, announced its recent acquisition of the marketing rights for Loncor ® 300 (florfenicol) from Elanco. With Loncor 300, Zoetis adds an amphenicol option ...

Investors were still wary of it after the latest earnings release. Zoetis slightly topped analyst estimates for profitability and met those for revenue in its fourth quarter. But as investors know ...

Parsippany, New Jersey-based Zoetis Inc. (ZTS) discovers, develops, and commercializes animal health medicines, vaccines, and diagnostic products and services. With a market cap of $74.8 billion ...

Companion animal product sales grew 8%, while livestock sales declined 3%. These results reflect Zoetis's strong operational capacity, despite facing challenges within the livestock segment.

CEO Kristin Peck highlighted Zoetis delivered an excellent 2024, achieving double-digit operational revenue growth of 11% and adjusted net income growth of 15%. U.S. and international revenues ...

Barclays raised the firm’s price target on Zoetis (ZTS) to $244 from $242 and keeps an Overweight rating on the shares. The company’s 2025 outlook “was not as bad as initial stock reaction ...